Therapeutics News and Research

RSS

Cytori receives U.S. patent allowance for key therapeutic methods for breast and soft tissue reconstruction products

Cytori Therapeutics, Inc. received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application that protects key therapeutic methods for its breast and soft tissue reconstruction products. This patent will protect Cytori's existing and future products when sold in the U.S.

31 Mar 2009

ImQuest presents data on the anti-hepatitis B virus activity of Pyrimidinediones

ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington D.C.

31 Mar 2009

Nile Therapeutics update on phase II CD-NP trial for acute heart failure

Nile Therapeutics, Inc. has announced that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile submitted to the U.S. Food and Drug Administration (FDA) to support the initiation of the Company's Phase IIb clinical trial with CD-NP for the treatment of acute heart failure, the FDA has placed CD-NP on clinical hold.

30 Mar 2009

Amicus Therapeutics presents positive results from phase 2 extension study of Amigal for Fabry disease

Amicus Therapeutics has announced positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal (migalastat HCL) for Fabry disease.

29 Mar 2009

Scientists discover structure of a protein that makes cancer cells resistant to chemotherapy

A research team at the Scripps Research Institute has obtained the first glimpse of a protein that keeps certain substances, including many drugs, out of cells.

29 Mar 2009

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

Experimental Parkinson's therapy may have robust weight-loss effect

A growth factor used in clinical experiments to rescue dying brain cells in Parkinson patients may cause unwanted weight loss if delivered to specific areas of the brain, according to University of Florida researchers in the March online edition of Molecular Therapy.

24 Mar 2009

Astrocytes help separate man from mouse

A type of brain cell that was long overlooked by researchers embodies one of very few ways in which the human brain differs fundamentally from that of a mouse or rat, according to researchers who published their findings as the cover story in the March 11 issue of the Journal of Neuroscience.

23 Mar 2009

Research yields potential target for cancer, wound healing and fibrosis

Research conducted by Allison Berrier, PhD, Assistant Professor of Oral and Craniofacial Biology at the LSU Health Sciences Center New Orleans School of Dentistry, and colleagues, provides insights that may help scientists design novel approaches to control wound healing and fight diseases such as cancer and fibrosis.

20 Mar 2009

Low dose medication best for treating high blood pressure

A newly published study found patients actually have more control of their high blood pressure (hypertension) when treated with less medication.

20 Mar 2009

MRSA study suggests strategy shift needed to develop effective therapeutics

USA300-the major epidemic strain of methicillin-resistant Staphylococcus aureus (MRSA) causing severe infections in the United States during the past decade-inherits its destructiveness directly from a forefather strain of the bacterium called USA500 rather than randomly acquiring harmful genes from other MRSA strains.

17 Mar 2009

Lung cancer: Molecular scissors determine therapy effectiveness

In the past few years, a number of anti-cancer drugs have been developed which are directed selectively against specific key molecules of tumor cells.

17 Mar 2009

Intradigm receives notice of allowance for key RNA interference patent covering potent siRNA sequence

Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, has announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance for a patent covering various aspects of a potent small interfering RNA (siRNA) sequence.

17 Mar 2009

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

Arno Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the use of AR-42.

17 Mar 2009

Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate

Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

17 Mar 2009

Discovery of new mechanism for the processing of endocannabinoids

New research funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, has identified a new mechanism for the processing of endocannabinoids, natural brain compounds similar to THC, the active ingredient in marijuana.

17 Mar 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

ADMEcell enters into manufacturing and distribution agreement with Advancell

ADMEcell, announced that it has entered into an exclusive agreement with Advancell, Barcelona, Spain, to manufacture and distribute the CacoReady System for the North American market.

15 Mar 2009

A model of melanoma generates hope for the use of targeted therapies

Researchers have developed a new mouse model that allows them to replicate normal pigment cells at the earliest stages of conversion to malignant skin cancer in humans.

12 Mar 2009